Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)

Trial Profile

Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms ABOUND 70+
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Sep 2017 Interim results assessing quality of life (QoL) in elderly NSCLC patients treated with nab- paclitaxel/carboplatin (nab-P/C), were presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 Data from this trial will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, according to a Celgene Corporation media release.
    • 06 Sep 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top